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Abstract
The effects of selenium, an essential nutrient with anti-carcinogenic properties, are mediated
by selenium-binding proteins. The protein expression status of human selenium-binding
protein 1 (SBP1) in human tumours and the exact function of this protein are not known.
In this study, quantitative two-dimensional polyacrylamide gel electrophoresis (2-D PAGE)
was used on 93 lung adenocarcinomas and ten uninvolved lung samples. Two likely isoforms
of a 56 kD protein that showed a significantly decreased abundance in lung adenocarcinomas
were observed. Tandem mass spectrometry and 2-D western blot analysis identified these two
proteins as human SBP1. Tumour tissue microarrays were utilized to examine the cellular
expression patterns of SBP1 using immunohistochemistry. The same tissue samples were
examined for SBP1 mRNA expression using oligonucleotide microarrays. Two major SBP1
isoforms were detected, with an acidic isoform (457) being significantly down-regulated
in lung adenocarcinomas compared with normal lung (p = 0.02). Two additional more
acidic SBP1 isoforms were only observed in normal lung. SBP1 protein isoforms and SBP1
mRNA levels were significantly decreased in poorly differentiated (versus moderately and
well-differentiated), T2–T4 (versus T1), and bronchus-derived (versus bronchioloalveolar)
tumours. Low levels of SBP1 protein (native form, 460) correlated significantly with poor
survival (p = 0.007). The lack of SBP1 expression was not due to gene deletion. Treatment
of A549 lung adenocarcinoma cells with the methylation inhibitor 5-azacytidine did not
affect expression of the SBP1 protein. Analysis of the tumour proliferation status using Ki-
67 suggests that down-regulated expression of SBP1 may reflect increased cell proliferation
and decreased differentiation in lung adenocarcinomas.
Copyright  2004 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
Epidemiological studies have suggested that an increa-
sed risk for certain human diseases, including cancer of
the lung, liver, colon, prostate, and pancreas, is related
to insufficient intake of selenium [1–3]. Supplementa-
tion of dietary selenium results in a significant reduc-
tion in total cancer mortality and incidence [4], espe-
cially in populations with low plasma selenium con-
centrations [5]. Proposed mechanisms for the protec-
tive role of selenium against cancer include inhibiting
carcinogen-induced covalent DNA adduct formation;
impeding oxidative damage to DNA, lipids, and pro-
teins; increasing apoptosis and inhibiting tumour cell
growth; altering DNA, RNA, and protein synthesis;
and increasing P53 and Cox-2 expression [1].
Mammalian selenium-containing proteins can be
divided into three groups: specific selenoproteins, non-
specific selenium-containing proteins, and selenium-
binding proteins [6,7]. The human selenium-binding
protein gene (SBP1, SELENBP1 or hSP56 ) [8] is
located at chromosome 1q21–22 and is the human
homologue of the mouse SP56 gene [9,10]. To date,
the protein expression status and the function of this
protein in lung cancer or other human tumours are not
known.
Two-dimensional polyacrylamide gel electrophore-
sis (2-D PAGE) and oligonucleotide arrays are power-
ful research techniques that have been widely used for
the detection and identification of potential tumour-
related gene products and genes [11,12]. Our previous
quantitative analysis of protein expression revealed
proteins showing significant changes in lung adenocar-
cinomas relative to normal lung tissue and associated
with other clinical variables including stage, tumour
differentiation, and survival [12,13]. In the present
study, multiple isoforms of human selenium-binding
protein 1 (SBP1) were identified as showing decreased
expression in lung adenocarcinomas, and the protein
and mRNA expression of SBP1 was examined in a
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large series of human lung cancers using a combined
proteomic and genomic-based approach.
Materials and methods
Tumour samples
Patients who underwent resections for lung cancer at
the University of Michigan Hospital from May 1991 to
July 2000 were evaluated for inclusion in this study.
Consent was received from all patients and the pro-
tocol was approved by the University of Michigan
Institutional Review Board (Medicine). All patient
identifiers were coded to protect confidentiality. All
lung tumours and adjacent normal lung tissues were
obtained immediately at the time of surgery. A por-
tion was embedded and frozen in OCT (Miles Scien-
tific, Naperville, IL, USA) for cryostat sectioning and
then stored at −80 ◦C until use. Haematoxylin-stained
cryostat sections (5 µm), prepared from tumour pieces
used for protein or mRNA isolation, were evaluated
by the study pathologist and compared with haema-
toxylin and eosin (H&E)-stained sections made from
formalin-fixed, paraffin wax-embedded tissue blocks
from the same tumours. All samples comprised more
than 70% tumour cells and none of the patients
received prior chemotherapy or radiotherapy. Tumours
were histopathologically divided into two broad cate-
gories: bronchus-derived (BD) if they exhibited inva-
sive features with architectural destruction, and bron-
chioloalveolar (BA) if they exhibited preservation of
lung architecture. A minimum of two H&E-stained
slides from each tumour were evaluated to assess lym-
phocytic response. Tumours were divided into two
broad categories based on the absence or presence
of a significant peri- and intra-tumoural lymphocytic
infiltrate. Sixty-four stage I lung adenocarcinomas, 29
stage III lung adenocarcinomas, and ten uninvolved
lung tissue samples were examined by quantitative 2-D
PAGE analysis. An additional 80 adenocarcinomas and
45 squamous lung tumours were added for immuno-
histochemical staining of tissue microarrays (TMAs).
2-D PAGE and mass spectrometry
Analytical 2-D PAGE protein quantification and iden-
tification by mass spectrometry were performed as
previously described [12,14]. Each gel generated
1600–2200 detectable spots, of which 820 spots were
selected for quantitative measurement in a total of 93
lung tumours and ten normal lung samples [12,14].
In this study, we selected two protein spots (457 and
460) on 2-D PAGE gels for further analysis. Tandem
mass spectrometry (ESI MS/MS) in a Q-TOF micro
(Micromass, Manchester, UK) was used for protein
identification.
Affymetrix oligonucleotide microarrays
RNA isolation and oligonucleotide microarray analysis
are described elsewhere [11]. In total, RNA from 86
adenocarcinomas and ten normal lung samples was
used in the analysis of SBP1 mRNA expression. Of
these, samples from 76 tumours and nine normal lungs
were also used in quantitative 2-D PAGE analyses.
The gene symbol of SBP1 on HuGeneFL Affymetrix
oligonucleotide microarrays (U95, Affymetrix, Santa
Clara, CA, USA) is SELENBP1 and the probe set
number is U29091 at.
2-D western blotting
Protein separation and 2-D western blotting were per-
formed as described previously [12]. Individual mem-
branes were incubated with anti-human SBP-1 anti-
body (mouse monoclonal antibody, M061-3, clone
4D4, MBL, Nagoya, Japan) at a 1 : 1000 dilution
(1 µg/ml). Following additional washes, membranes
were incubated with a secondary antibody conjugated
to horseradish peroxidase (HRP) at a 1 : 5000 dilution
for 1 h, then washed, and incubated for 1 min with
enhanced chemiluminescence (ECL) (Pierce, Rock-
ford, IL, USA) and exposed to film (Amersham, Pis-
cataway, NJ, USA).
Immunohistochemical staining and tissue
microarray
A TMA was constructed, as previously described
by Kononen et al [15], using formalin-fixed, paraf-
fin wax-embedded tissues from 148 pulmonary ade-
nocarcinomas and 45 squamous tumours in addition
to representative normal lung tissues. Three repli-
cate tumour-rich tissue cores were sampled from
each of the selected tissues. Immunohistochemical
staining was performed on the DAKO Autostainer
(DAKO, Carpinteria, CA, USA) using DAKO LSAB+
and diaminobenzadine (DAB) as the chromogen. De-
waxed and rehydrated sections of the TMA at 4-µm
thickness were labelled with SBP-1 antibody (mouse
monoclonal antibody, clone 4D4, MBL, Nagoya,
Japan; 1 : 500 dilution) after microwave citric acid epi-
tope retrieval. Slides were lightly counter-stained with
haematoxylin. Each sample was then scored using a
scale of negative (–), weak (+), moderate (++), and
strong staining (+++).
MIB-1 (1 : 100) (DAKO, Carpinteria, CA, USA)
was used to analyse nuclear expression of the Ki-67
cell proliferation antigen. The proliferative index of
each tumour was determined by counting more than
1000 nuclei from each tumour and determining the
percentage of labelled cells to the total cell number
[16].
A549 and SKLU1 cell culture and 5-azacytidine
and dexamethasone treatment
A549 and SKLU1 cell lines were obtained from
the American Tissue Culture Collection (ATCC) and
grown in DMEM with 10% fetal bovine serum (FBS).
A549 was cultured in the presence of 5-azacytidine
(2.5 or 5 µM, Sigma, St Louis, MO, USA) and
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Figure 1. 2-D PAGE and 2-D western blotting of SBP1 protein. (A) Digital image of a silver-stained 2-D PAGE separation of a
lung adenocarcinoma showing the region containing SBP1 protein spots separated by molecular mass (MW) and isoelectric point
(pI). (B) 2-D western blot results in normal lung, a lung tumour, and the A549 cell line. Four isoforms of SBP1 protein were
identified in normal lung (spots a, b, 457, and 460) and two isoforms in tumours (spots 457 and 460). Spot 460 is the proposed
native form and the other three are likely phosphorylated forms. A very low abundance of native SBP1 (spot 460) and high levels
of the degradation form (spot c) were found in the A549 cell line
dexamethasone (0.125 or 0.25 µM), respectively, for
3 days and then washed three times with PBS prior
to protein isolation and subsequent analysis using
western blotting [17].
Chromosome 1q21 LOH analysis
DNA isolation and preparation were performed as pre-
viously described [18]. Primers (forward, 5′-ttgagaact-
gccttagactgc-3′; reverse, 5′-cccaagttgctggaacc-3′) were
designed for D1S2347, a sequence tagged site ∼20 kb
centromeric from SELENBP1. Forward primers were
end-labelled with [γ -32P]ATP (NEN Life Science
Products, Boston, MA, USA) using T4 polynucleotide
kinase (New England Biolabs, Beverly, MA, USA).
PCR was performed using Taq polymerase (Promega,
Madison, WI, USA), and the PCR products (232–294
bp in size) were resolved on 8% denaturing poly-
acrylamide gels. Heterozygous individuals were then
analysed for loss of one or both alleles using Image-
Quant software (Molecular Dynamics, Sunnyvale, CA,
USA). Results were repeated and verified.
Statistical analyses
F -tests were used for testing the difference between
SBP1 protein levels and in each clinicopathologically-
defined group except the tumour–normal comparisons,
for which T -tests were used. The Pearson correlation
coefficient method was used for the correlation anal-
ysis between the levels of SBP1 protein and Ki-67
expression. Kaplan–Meier survival curves and the log-
rank test were used for survival analyses.
Results
SBP1 protein identification and verification
A silver-stained 2-D PAGE gel showing the region
containing the SBP1 polypeptides in a lung adenocar-
cinoma is shown in Figure 1A. These protein spots
(457 and 460) were identified as SBP1 using tandem
mass spectrometry (Figure 2). Spot 460 was judged
as the native form based on molecular weight and pI.
The more acidic spot (457) likely represents a phos-
phorylated form based on its 2-D gel location. The
identity of these proteins was further verified by 2-D
western blotting with an anti-human SBP1 antibody
(Figure 1B). Interestingly, 2-D western blot analy-
sis also identified two additional isoforms of SBP1
that could only be detected in normal lung samples.
These immunoreactive isoforms are of similar molec-
ular weight but are more acidic, and likely represent
bi- or tri-phosphorylated forms. Due to very low abun-
dance on 2-D gels of lung adenocarcinomas, these two
isoforms could not be quantitatively analysed in all
samples. The acidic isoform SBP1 (spot 457) corre-
lated strongly with the native form SBP1 (spot 460)
using Pearson correlation coefficient analysis (r = 0.8,
p < 0.001). Very low expression levels of the native
isoform (spot 460) and an apparent degradation form
(spot c) of the SBP1 protein were found in 2-D western
blot analysis of A549 cells (Figure 1B).
Quantitative 2-D PAGE analysis of the 93 lung ade-
nocarcinomas and the ten uninvolved lung samples
revealed that the level of the acidic SBP1 (457) pro-
tein was significantly decreased in lung adenocarcino-
mas, compared with normal lung samples (p = 0.02)
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Figure 2. Identification of SBP1 using tandem mass spectrometry (ESI MS/MS). (A) Eighteen peptides (eight shown here)
of the native isoform of SBP1 (spot 460) were matched to a non-redundant database using ProteinLynx Global SERVER
(http://www.micromass.co.uk/) with a total score of 3901.4 and coverage of 19.9%. (B) ESI MS/MS figure of a peptide in A
(bold). (C) SBP1 protein sequence with matched peptides (highlighted areas). Eight peptides of the acidic isoform of SBP1 (spot
457) were matched with a total score of 1112.3 and coverage of 15.1% (figure not shown)






X ± SD p (T test)
Fold change
Tumour/normal
457 0.17 ± 0.07 0.11 ± 0.14 0.02 0.6
460 0.11 ± 0.12 0.12 ± 0.15 0.72 1.1
Ratio 457/460 1.63 ± 0.55 1.04 ± 0.99 0.01 0.6
Sum (457 + 460) 0.28 ± 0.08 0.23 ± 0.26 0.14 0.8
mRNA 880.3 ± 254.5 742.9 ± 704.7 0.22 0.8
∗ Mean value.
(Table 1). The ratio of 457/460 was also significantly
decreased in lung adenocarcinomas (p = 0.01). The
native form of SBP1 (460) and the sum of spots
457 and 460 were not significantly different between
tumour and normal lung, consistent with the simi-
lar mRNA levels determined using oligonucleotide
microarrays (Table 1). This observation reflects the
commensurate mRNA and protein expression levels
between well-differentiated tumours and normal lung
(Figures 3A–3C).
SBP1 is decreased in clinically aggressive tumours
and related to poor outcome
Quantitative analysis of protein spots revealed decre-
ased levels of both SBP1 isoforms (457 and 460) in
poorly differentiated adenocarcinomas, compared with
moderately or well-differentiated tumours (Table 2,
p < 0.038 and 0.001, respectively, Figures 3A
and 3B). The levels of these two isoforms were also
decreased in T2–T4 tumours (versus T1), bronchus-
derived (versus bronchoalveolar) tumours, and tum-
ours with a positive lymphocytic response (versus
negative lymphocytic response) (Table 2). A simi-
lar relationship was observed for SBP1 mRNA lev-
els (Table 2 and Figure 3C) and, interestingly, SBP1
mRNA levels were also decreased in tumours show-
ing nuclear accumulation of P53 and in male patients
(Table 2). The SBP1 protein and mRNA levels were
not influenced by patient age, smoking status, tumour
stage, lymph node status or K-ras 12th/13th codon
mutations. Importantly, low levels of SBP1 protein
(460) correlated significantly with poorer survival
in patients with lung adenocarcinomas (p = 0.007)
(Table 2 and Figure 3D).
Cytoplasmic and nuclear localization of SBP1 in
lung tumours
To verify the 2-D PAGE results and uncover SBP1
cellular distribution, immunohistochemistry (IHC) was
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Table 2. Relationship between SBP1 and clinicopathological variables in lung
adenocarcinoma
Variables n p (457) p (460) p (mRNA)
Age, years
<65 49 0.327 0.537 0.545
>65 44
Gender:
Male 40 0.781 0.541 0.038 down∗
Female 53
Smoking:
Smoking 79 0.498 0.621 0.442
Non-smoking 10
Stage:
Stage III 29 0.643 0.172 0.079
Stage I 64
T status
T2–T4 44 0.042 down 0.0106 down 0.007 down
T1 49
N status
N0 68 0.503 0.219 0.185
N1, N2 25
Classification
Bronchus-derived 76 0.0418 down 0.0006 down 0.008 down
Bronchioloalveolar 14
Differentiation




Yes 41 0.0137 down 0.0078 down 0.006 down
No 52
P53 nuclear accumulation
Positive 28 0.108 0.162 0.00004 down
Negative 54
K-ras 12th/13th codon mutation
Positive 36 0.307 0.592 0.965
Negative 40
Survival† 90 0.05 0.007 0.07
∗ p value of F-test (protein) or T-test (mRNA); down: decreased.
† Log-rank test; the median value was used as the cut-off value. Dead/alive: 43/50.
performed on formalin-fixed, paraffin wax-embedded
lung TMAs (Figure 4A) containing ten normal and
193 neoplastic lung samples (148 adenocarcinomas
and 45 squamous lung cancers). Higher levels of SBP1
protein were noted among pulmonary epithelial cells
in normal lung tissues (Figure 4B). Positive cytoplas-
mic and nuclear staining for SBP1 was observed in
lung adenocarcinomas (138/148, 93.2%), especially
in well-differentiated tumours (Figure 4C). Reduced
expression was noted in poorly differentiated tumours
(Figure 4D). A much lower percentage of squamous
tumours (7/45, 16%) showed positive SBP1 staining.
No expression was detected in the A549 adenocarci-
noma cell line. A strong correlation was found between
SBP1 staining intensity using IHC and quantitative
2-D PAGE analysis of spot 457 or 460 (r = 0.4,
p < 0.001).
Decreased SBP1 protein levels in highly
proliferative adenocarcinomas
To assess SBP1 expression relative to cell prolifera-
tion, the proliferation index was determined in 62 of
the primary lung adenocarcinomas in the tumour TMA
using the MIB-1 antibody to the Ki-67 antigen. As
expected, Ki-67 antigen expression and proliferation
rates were higher in poorly differentiated than in well
or moderately differentiated tumours [15]. There was a
significant negative correlation between SBP1 protein
staining assessed using IHC and Ki-67 antigen stain-
ing in lung adenocarcinomas (r = −0.97, p = 0.002)
using Pearson correlation coefficient analysis. This
indicates that SBP1 protein expression is decreased
in highly proliferating lung tumours.
SBP1 is not increased following 5-azacytidine
(5-AC) or dexamethasone treatment
To determine whether hypermethylation might cause
SBP1 gene silencing, the A549 cell line was treated
with 5-AC for 3 days. These cells express very low
levels of native SBP1 protein. SBP1 protein expres-
sion remained unchanged after treatment with either
5-AC or dexamethasone (Figure 5A). SKLU1 lung
adenocarcinoma cells also do not express SBP1 protein
(Figure 5A, lane 7).
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Figure 3. Lung differentiation, patient survival, and SBP1 expression. (A) Box plots showing that the levels of the acidic
isoform of SBP1 (457) were significantly decreased in poor (P) or moderately differentiated (M) adenocarcinomas compared
with well-differentiated (W) tumours or normal lung samples. The numbers in parentheses indicate the sample number in
each differentiation group. (B) The levels of the native form of SBP1 (460) were also significantly decreased in poor or
moderately differentiated adenocarcinomas compared with well-differentiated tumours or normal lung samples. (C) Decreased
levels of SBP1 mRNA in poorly or moderately differentiated tumours compared with well-differentiated tumours or normal lung.
(D) Kaplan–Meier survival curves showing that decreased expression of the native isoform of SBP1 (460) correlated significantly
with poor patient survival. Log-rank test; the median value was used as the cut-off value. Sixteen of 45 patients died in the high-level
expression group and 27 of 45 died in the low-level expression group
The SBP1 genomic region is not deleted
To determine whether genomic deletion might explain
the lower SBP1 expression in the lung adenocarci-
noma, polymorphic markers for this region were used
in a competitive PCR-based assay. LOH was not
detected in the SBP1 region in the six informative
cases that showed no or very low expression levels of
SBP1 mRNA and/or protein expression (Figure 5B).
Discussion
Increasingly advanced genomic and proteomic tech-
niques allow complex and high-throughput compar-
isons to be made for the purpose of elucidating
genes that impel or suppress tumour growth, invasion,
and lethality. Inherent in each technique, however,
are certain advantages and limitations, as have been
thoroughly described [19–21]. In the present study,
complementary methods have been used to verify
results observed with other techniques. Quantitative
2-D PAGE analysis of 93 lung tumours and ten nor-
mal lung specimens uncovered two protein isoforms
that were significantly decreased in more aggressive
tumours. Tandem mass spectrometry identified these
two proteins as human isoforms of SBP1 and these
results were subsequently verified by 2-D western blot-
ting. Tumour tissue microarrays were utilized to exam-
ine the cellular localization of SBP1 using IHC and to
verify the results obtained by 2-D PAGE analyses.
To date, two kinds of selenium-binding protein,
SBP1 (or SP56) and SBP2 (or AP56), have been
identified in mouse liver [22,23]. The mRNA levels
of hSP56 (SP56/AP56 ) were reported to be high in
normal human liver, lung, kidney, colon, prostate, and
pancreas [24]. Examination of the mRNA, however,
cannot distinguish between hSP56 and a putative
human AP56 due to only a 24-nucleotide difference
within the coding region [25]. We identified two
isoforms of SBP1 protein (acidic form 457 and native
form 460), both of which have a molecular weight
of 56 kD and have an approximate pI of 6.3–6.6 in
human lung cancers. This protein is different from the
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Figure 4. Immunohistochemical analysis of SBP1 with TMAs. (A) A portion of the lung TMA, stained with the anti-SBP1 antibody,
showing different staining intensities (brown is positive staining and yellow is an orientation marker). The paraffin wax-embedded
tissue from 148 pulmonary adenocarcinomas, 45 squamous tumours, and representative normal lung tissues are included. Three
replicate tumour-rich tissue cores were sampled from each of the selected tissues ×10. (B) Higher levels of SBP1 protein
expression were observed among pulmonary epithelial cells in normal lung samples (arrow indicating positive staining). (C) Higher
levels of cytoplasmic and nuclear SBP1 staining in a well-differentiated adenocarcinoma (arrow). (D) Low-level staining of SBP1 in
a poorly differentiated adenocarcinoma (arrow). (B–D) ×400. Only 7/45 (16%) squamous tumours showed weak positive SBP1
staining. No SBP1 protein expression was observed in the A549 adenocarcinoma cell line (not shown)
selenoprotein and selenoprotein-P that were previously
identified in human lung adenocarcinoma cells and
prostate cancer, respectively [26,27]. Interestingly, two
additional isoforms of SBP1 were identified and were
only present in normal lung samples using 2-D western
blot analysis. These two isoforms have the same
molecular weight but are more acidic, and likely
represent bi- or tri-phosphorylated forms of SBP1.
The possible structural differences between these four
SBP1 isoforms are unknown.
The mechanism by which selenium binds to this pro-
tein and the exact function of SBP1 are unknown. It
has been proposed that SBP1 (or SBP56) may partic-
ipate in the late stages of intra-Golgi protein transport
[28], and have a growth-inhibitory role in mouse liver
[23]. SBP1 mRNA is expressed in the slow-growing,
androgen-sensitive human prostate cancer cell line
LNCaP, but is not expressed in either of two more
rapidly growing, androgen-insensitive human prostate
cancer cell lines, PC-3 and DU145 [24]. The levels
of selenoprotein-P mRNA, however, are significantly
decreased in a subset of prostate cancers and in the
LNCaP and PC-3 cell lines compared with normal
prostate tissue [27]. In our study, the acidic form of
SBP1 (457) and the ratio of 457/460 were signifi-
cantly decreased in lung adenocarcinomas compared
with normal lung. The native SBP1 protein and mRNA
levels were not significantly different between tumour
and normal lung, most likely a result of the simi-
lar protein levels observed in normal lung and well-
differentiated tumours (Figures 3A–3C). Low lev-
els of SBP1 protein are observed in tumours from
patients with poor survival. When comparing sub-
groups of tumours, both SBP1 protein and mRNA
levels were significantly decreased in poorly differ-
entiated, T2–T4, and bronchus-derived tumours, indi-
cating that down-regulated expression of SBP1 occurs
in larger and potentially more aggressive lung adeno-
carcinomas.
Two isoforms of SBP2 protein have been previously
identified in mouse liver [29,30]. SBP2 expression is
dramatically decreased after treatment with ciprofi-
brate, which increases cell proliferation. Dexametha-
sone, an inhibitor of cell proliferation in lung cells,
can significantly increase SBP2 protein expression in
liver [29]. However, dexamethasone did not increase
SBP1 expression in the A549 cell line (Figure 5A).
Furthermore, treatment of this cell line with 5-AC
(Figure 5B) did not result in elevated expression of
SBP1. This suggests that SBP1 may not be silenced
by gene methylation. We also examined tumours that
showed lack of SBP1 expression for potential genomic
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Figure 5. SBP1 induction assays and gene LOH analysis. (A) Expression of SBP1 protein following treatment with varying
concentration of dexamethasone (DX) and 5-azacytidine (5-AC) in the A549 cell line. Top panel, increased SBP1 protein
expression was not detected in A549 cells following treatment with either DX or 5-AC (arrow). Two apparent smaller
degradation bands were only found in the A549 cell line. Lane 1: normal lung tissue; 2: control (no treatment); 3: DX 0.125 µM;
4: DX 0.25 µM; 5: 5-AC 2.5 µM; 6: 5-AC 5 µM; 7: SKLU1 cell line, which does not express SBP1 protein; bottom panel, β-actin
was used as a loading control. (B) LOH analysis of the SBP1 gene region in lung adenocarcinomas. LOH was not detected in
informative cases from 12 patient samples. T indicates tumour and N indicates the patient’s corresponding normal lung DNA
deletion and did not detect these alterations. We did
find, however, that there is a significant negative cor-
relation between SBP1 protein expression and Ki-67
antigen staining, suggesting that lower SBP1 expres-
sion is present in highly proliferative lung tumours.
Immunohistochemical analysis using an anti-human
SBP1 antibody showed positive cytoplasmic and
nuclear protein staining in lung adenocarcinomas and
in normal pulmonary epithelial cells. Much lower lev-
els of expression were detected in squamous lung
tumours (16%, 7/45 positive staining), which is con-
sistent with a recent report on mRNA levels [31] indi-
cating that SBP1 expression is also tissue-specific. The
reason for decreased SBP1 in tumours with a positive
lymphocytic response may reflect a higher percentage
of BD tumours (78.1%, 32/41) and a lower percentage
of BA tumours (4.9%, 2/41) in the positive than in the
negative lymphocytic response group (55.8%, 29/52
for BD; 17.3%, 9/52 for BA, respectively). The sele-
nium compound selenodiglutathione can induce p53
protein levels in ovarian cells (A2780) that contain
wild-type p53 [32]. We found that only SBP1 mRNA,
and not protein, was increased in tumours that did
not show p53 nuclear protein accumulation (an indica-
tion of mutant p53), suggesting that SBP1 may induce
wild-type p53 expression in lung tumours. We also
found that SBP1 mRNA was decreased in male lung
cancer patients; however, the protein levels did not
change significantly. This is different from the mouse
SBP2 protein, which is expressed at higher levels in
males than in female mice [29].
To our knowledge, this is the first report that
multiple isoforms of human SBP1 are expressed in
lung tissue and that low levels of SBP1 protein
are related to worse survival in patients with lung
adenocarcinomas. Both the SBP1 protein and mRNA
were significantly decreased in poorly differentiated
and bronchus-derived tumours. Low levels of SBP1
expression were present in tumours with a higher
proliferation status and in squamous lung tumours.
SBP1 may have clinical potential as a marker for
patient outcome, but understanding the regulation of
phosphorylation of the different isoforms, the basis for
reduced SBP1 expression, and its role in lung cancer
will require further study.
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